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In this issue, M.H.Hazbón (1) reviews recent
advances in molecular methods for early diagnosis
of tuberculosis and drug-resistant tuberculosis.
This article has much in common with other “state
of the art” reviews that have been appearing in
the world’s literature on molecular tuberculosis
(TB) diagnostics for some time now. Most of these
reviews are well written, factual accounts of
advances in this important field of research. In
the last two decades much has been stated and
even more has been promised about the role of
genomics in providing alternatives to the
conventional methods that have been used for
over a century.
Emphasis is often given to the development of
new diagnostic tools with turn-around times
measured in hours rather than days, weeks or
months. However, in practical terms, very little of
what is often described with such vigorous
enthusiasm offers actual relief to the modern TB
laboratory specialists or indeed much of a
challenge to the old, conventional, smear
microscopy and drug susceptibility testing (DST).
As the author of the above article laments, only
two of these methods, based on nucleic acid
amplification and detection of specific
mycobacterial sequences and mutations, have
been approved (2,3) by the Food and Drug
Administration (FDA) in the USA.
Moreover, the approval for the test was given only
for AFB smear-positive respiratory specimens in
the case of the Amplicor test, and for either smear
positive or negative respiratory specimens in the
case of the Enhanced Mycobacterium
tuberculosis test (E-MTD). This is far from the
stellar performance that the sophistication of the
technologies used could have allowed us to expect
and indeed demand. However, the recent
sequencing of M. tuberculosis’s genome will
eventually lead to the deciphering of the meaning
of much genetic information and the creation of
truly novel TB diagnostics.
The status of the "replacements" for the other
mainstay of TB diagnostics, i.e. drug susceptibility
testing, is even less advanced. Not only there has
not been regulatory approval for the new tests but
it has become evident over time “that the presence
or absence of mutations in drug resistance
associated genes does not necessarily indicate
susceptibility or resistance to the corresponding
drug” (1). Isolates with mutations in DR-associated
genes can show phenotypic susceptibility and
viceversa. The so-called “real resistance-
mutations” can be clinically relevant, but their
absence doesn’t necessarily mean drug
susceptibility. These circumstances mean that test
results obtained with these methods must always
be confirmed by results obtain phenotypic
methods (4-6).
The existence of multiple mutations conferring re-
sistance to a given drug have dampened early
enthusiasm for these methods. Even DNA
sequencing, the “gold standard” for the detection
of drug mutations, requires several sequencing
reactions per isolate, and is unlikely to be used
routinely, except for r ifampicin. Other
disadvantages include high costs, the need for
sophisticated equipment and expertise, the
technical difficulty in the performance of this tests
and frequent contamination problems. Had some
of these tests been developed half a century ago,
physicians would have been clamouring for a more
*Janus is the Roman god of gates and doors, beginnings
and endings and hence represented with a double-faced
head, each looking in opposite directions. It also represents
the transition between primitive life and civilization, the
countryside and the city and the growing-up of young people.
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“holistic” test, that would also take into account
the expression and the modulation of genetic in-
formation, in fact a “phenotypic “ test!
As for the advantages of these tests, there are
obvious and should not be overlooked: some can
yield direct, rapid DST results and even detect M.
tuberculosis at the same time, albeit not always
with higher specificity or sensitivity than
conventional technology. The molecular analysis
of resistance can yield important information not
available through conventional testing. Genotypic
analysis also can detect specific mutations which
identify strains with high levels of resistance or
broad spectrum of resistance. As well, the
assignment of specific mutations could become
an epidemiological marker for resistant strains (7).
So, how have we advanced in the last 20 years in
terms of easing the heavy laboratory TB diagnostic
burden in high endemic (HEC)-low resource
countries? The answer is: not very far, since very
few of these tests have reached the level of field
testing and none have received regulatory approval
in developed countries or are in routine use in
NTP’s of HEC’s.
This brings us to smear microscopy, the mainstay
of TB diagnosis in countries bearing  99% of the
world’s TB disease burden, the old test that the
FDA approved tests were designed to replace.
Smear microscopy is very “low tech“, admittedly
not very sensitive and “unpleasant” to perform, it
nevertheless yields rapid  and specific results in
the field. Should we not improve it rather than
replace it with a “new” test? Attempts at increasing
its sensitivity have unfortunately but predictably
failed, i.e. any gain in sensitivity has usually been
made at the expense of specificity. There would
be, however, much practical value in improving
its “ease of use” and making it totally safe for
handling clinical specimens on the open bench,
at least until new sophisticated research can
provide a viable alternative for HEC’s. As far as
DST methods are concerned the "gold standard"
will remain unchanged for the foreseeable future.
For too long now the bacterial cell has been re-
duced, in the minds of many, to a small recep-
tacle full of nucleic acids. The reality is by far more
complex, genetic information is processed and will
be either repressed or expressed. As far as re-
search in applied TB molecular diagnostics is con-
cerned, one would wish that the current fad of
genomics could recede somewhat thus giving
newer technologies based on alternative disci-
plines, such as proteomics and lipomics, a much
needed chance. Let us hope that the gatekeepers
who like the Roman god Janus opened the door
into genomics for TB diagnostics, will show their
other face and reopen the door leading to other
methodological fields of TB diagnostics research.
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